Stevens's Thesis: Was the 1968 Prohibition Evidence-Based?

“Stevens argued the 1968 scheduling was politically driven, not evidence-driven. The WHO Critical Review, the FDA Breakthrough Therapy designations, and the Phase 3 clinical results have all confirmed this (Source not found; under review).”

The claim: The 1968 Staggers-Dodd Act and the 1970 Controlled Substances Act's Schedule I classification of LSD ended a clinical research program that had produced genuine evidence of therapeutic efficacy, not because the evidence was wrong but because the political and institutional conditions had become untenable. The scheduling was political, not scientific.

The evidence that the scheduling was not scientific: The WHO Expert Committee on Drug Dependence conducted a Critical Review of LSD in 2019 and found no evidence supporting the substance's current international scheduling level (Source not found; under review). The FDA's Breakthrough Therapy Designation for psilocybin (2018), a compound with nearly identical pharmacological mechanism to LSD, effectively acknowledged that classical psychedelics may have accepted medical use, contradicting the Schedule I criterion.

The resumption confirms what was interrupted: The industry Phase 3 trials (2025-2026) produced statistically significant results for psilocybin in treatment-resistant depression. A 2012 meta-analysis by Krebs and Johansen of six randomized controlled trials of LSD for alcoholism from the 1960s-70s found a statistically significant positive effect on drinking behavior. The clinical evidence that existed in 1968 was real.

The LSD safety data: The 2016 Global Drug Survey found LSD had the lowest emergency medical treatment rate of any substance surveyed. Zero overdose deaths from LSD toxicity have been documented in eighty years of use. The pharmacological evidence for Schedule I's 'high abuse potential, no accepted medical use' designation was absent in 1968 and remains absent.

Verdict: Was right. The 1968 scheduling was not driven by evidence of harm or lack of efficacy. It was driven by the political association of LSD with the counterculture, by Ehrlichman's explicitly racially targeted drug war strategy, and by the institutional desire to control what could not be controlled. The clinical research that resumed fifty years later is confirming what was interrupted.

Sources

• Stevens, Storming Heaven (1987)
• WHO ECDD Critical Review LSD (2019) [Source not found; under review]
• Industry Phase 3 psilocybin trials (2025-2026)
• Krebs & Johansen, J. Psychopharmacol. (2012)